Dr. James Francis Dylewski, DO

Dr. Dylewski practices at Denver Health Medical Center in Denver, Colorado, part of Denver Health and Hospital Authority.

Dr. Dylewski's NPI, 1124314869, was assigned on June 21, 2011. Dr. Dylewski holds Colorado license DR.0059575.

Dr. Dylewski's primary practice is Denver Health Medical Center, at 777 Bannock St, Denver, CO 80204 in Denver County. The practice phone is (303) 602-4935.

Dr. Dylewski's primary practice is Denver Health Medical Center in Denver, Colorado, part of Denver Health and Hospital Authority. The medical group on file is Denver Health. Dmand AI also links Dr. Dylewski to 1 more dialysis center, named with a free account. Dr. Dylewski's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dylewski practices, 2 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Dylewski's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Dylewski is board certified in internal medicine by the American Board of Internal Medicine. Dr. Dylewski is licensed in Colorado.

CMS data shows 196 Medicare services from Dr. Dylewski across 5 procedure codes in 2024, for 62 Medicare patients. Medicare paid $30,376 for them.

CMS counts 62 Medicare patients who saw Dr. Dylewski in 2024. The largest group is 65 to 74, with 28 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 81% are also on Medicaid. Their average risk score is 5.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dylewski's median patient age at 67, with 49% women.

In 2024, Dr. Dylewski wrote 208 Medicare Part D claims for 65 patients. 70% of them were for generic drugs. CMS names the drug for 111 of them, across 8 drugs with 11 or more claims each, at $377,522 in total drug cost. In 2023, CMS named 52 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 97 out of 100 for Dr. Dylewski for performance year 2024, reported as part of a group. Dr. Dylewski accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 11 papers to Dr. Dylewski, published from 2018 to 2023. 2019 was the busiest year, with 4. The most frequent topics are Podocytes, Histocompatibility Antigens Class I and Receptors, Fc. Dr. Dylewski has published most often in PLoS One. Dr. Dylewski's most frequent co-authors are Sarah E. Panzer, MD, Sophia Louise Ambruso, DO and Anip Bansal, MD.

CMS Open Payments shows 6 general payments to Dr. Dylewski from 3 drug and device companies in 2024. Consulting fees make up the largest share, 66% of the total. Calliditas Therapeutics US Inc. paid the most, $2,047.